An experimental drug shows promise as an effective new approach for treating multiple sclerosis and the intestinal ailment Crohn's disease. In preliminary tests, the new drug Antegren dramatically ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression. In recent years, the management of multiple ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

Doctors have traditionally used a "step-up," also known as the "escalation," approach for treating multiple sclerosis (MS), the neurodegenerative disease that affects the central nervous system. Using ...

Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...

An estimated 2.8 million people worldwide are living with multiple sclerosis (MS), according to the National MS Society.

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Expert Rev Neurother. 2010;10(5):791-809. As of 9 February 2010, 35 cases of progressive multifocal leukoencephalopathy (PML) were diagnosed in more than 64,000 patients having received natalizumab ...